FI943838A0 - Vinyleeniatsaindolijohdannaiset ja menetelmä niiden valmistamiseksi - Google Patents

Vinyleeniatsaindolijohdannaiset ja menetelmä niiden valmistamiseksi

Info

Publication number
FI943838A0
FI943838A0 FI943838A FI943838A FI943838A0 FI 943838 A0 FI943838 A0 FI 943838A0 FI 943838 A FI943838 A FI 943838A FI 943838 A FI943838 A FI 943838A FI 943838 A0 FI943838 A0 FI 943838A0
Authority
FI
Finland
Prior art keywords
vinylenazaindole
derivatives
preparation
variables
rest
Prior art date
Application number
FI943838A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943838A7 (fi
Inventor
Franco Buzzetti
Angelo Crugnola
Dario Ballinari
Felicita Greco
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of FI943838A7 publication Critical patent/FI943838A7/fi
Publication of FI943838A0 publication Critical patent/FI943838A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
FI943838A 1992-12-23 1994-08-19 Vinyleeniatsaindolijohdannaiset ja menetelmä niiden valmistamiseksi FI943838A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929226855A GB9226855D0 (en) 1992-12-23 1992-12-23 Vinylene-azaindole derivatives and process for their preparation
PCT/EP1993/003536 WO1994014808A1 (en) 1992-12-23 1993-12-15 Vinylene-azaindole derivatives and process for their preparation

Publications (2)

Publication Number Publication Date
FI943838A7 FI943838A7 (fi) 1994-08-19
FI943838A0 true FI943838A0 (fi) 1994-08-19

Family

ID=10727139

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943838A FI943838A0 (fi) 1992-12-23 1994-08-19 Vinyleeniatsaindolijohdannaiset ja menetelmä niiden valmistamiseksi

Country Status (24)

Country Link
US (1) US5397787A (enExample)
EP (1) EP0626963B1 (enExample)
JP (1) JP3507497B2 (enExample)
KR (1) KR950700296A (enExample)
CN (1) CN1093707A (enExample)
AT (1) ATE181074T1 (enExample)
AU (1) AU670488B2 (enExample)
CA (1) CA2126228A1 (enExample)
DE (1) DE69325262T2 (enExample)
DK (1) DK0626963T3 (enExample)
ES (1) ES2134926T3 (enExample)
FI (1) FI943838A0 (enExample)
GB (1) GB9226855D0 (enExample)
GR (1) GR3030941T3 (enExample)
HU (1) HUT67431A (enExample)
IL (1) IL108087A (enExample)
MX (1) MX9400206A (enExample)
MY (1) MY109695A (enExample)
NZ (1) NZ259330A (enExample)
PL (1) PL304894A1 (enExample)
RU (1) RU94040390A (enExample)
TW (1) TW296383B (enExample)
WO (1) WO1994014808A1 (enExample)
ZA (1) ZA939578B (enExample)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
AU5645196A (en) * 1995-04-11 1996-10-30 Lonza A.G. Process for preparing azaindoles with an activated copper ch romite catalyst by catalytic dehydrocyclisation of alkylpyri dylamines (pyridopyridines)
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO1996040648A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ATE292623T1 (de) * 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US20040067531A1 (en) * 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
UA72448C2 (en) * 1997-09-26 2005-03-15 Zentaris Gmbh Azabenzimidazole-based compounds, methods for their synthesis and pharmaceutical composition, method for modulating function of serine/threonine protein kinases with azabenzimidazole-based compounds, method for identifying compounds modulating functioning of serine/threonine protein kinase, method for preventing and treating serine/threonine protein kinase-related abnormal conditions with azabenzimidazole-based compounds
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
US5935626A (en) * 1997-11-24 1999-08-10 Moorman Manufacturing Company Weather resistant mineral feeds and methods of making same
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
CA2318403A1 (en) 1998-01-21 1999-07-29 Sugen, Inc. Human orthologues of wart
JP2002507598A (ja) * 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
WO1999053036A2 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
US6525072B1 (en) 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
ATE234830T1 (de) * 1998-12-17 2003-04-15 Hoffmann La Roche 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
AU767138B2 (en) 1998-12-17 2003-10-30 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
EP1630559A3 (en) * 1998-12-30 2006-06-07 Sugen, Inc. PYK2 (RAFTK) and inflammation
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
JP2002540096A (ja) * 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
TR200103789T2 (tr) * 1999-04-06 2002-04-22 Knoll Gmbh Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6835546B1 (en) 1999-10-22 2004-12-28 Pharmacia & Upjohn Company Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
ES2267605T3 (es) 1999-12-22 2007-03-16 Sugen, Inc. Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
CN1422262A (zh) 2000-02-07 2003-06-04 艾博特股份有限两合公司 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
AU2001241798A1 (en) 2000-02-28 2001-09-12 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
AR036042A1 (es) 2001-05-30 2004-08-04 Sugen Inc Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7005444B2 (en) 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
CA2461812C (en) 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
BR0213185A (pt) 2001-10-10 2004-09-14 Sugen Inc Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
IL164082A0 (en) * 2002-03-28 2005-12-18 Eisai Co Ltd Azaindole derivatives and pharmaceutical compositions containing the same
BR0308985A (pt) * 2002-04-03 2005-01-04 Allergan Inc (3z)-3-(3-hidro-isobenzofuran-1-ilideno)-1,3-diidro-2h-i ndol-2-onas como inibidores da cinase
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
EP2430923A1 (en) 2002-06-05 2012-03-21 Genentech, Inc. Compositions and methods for liver growth and liver protection
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ATE375342T1 (de) 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US6699863B1 (en) 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US7105562B2 (en) 2003-08-06 2006-09-12 Sugen, Inc. Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
BRPI0415395A (pt) * 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
US7718676B2 (en) 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
AR048518A1 (es) 2004-04-02 2006-05-03 Osi Pharm Inc Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7915443B2 (en) 2006-11-16 2011-03-29 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
TW200616632A (en) * 2004-06-17 2006-06-01 Plexxikon Inc Compounds modulating c-kit activity and uses therefor
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
UA95071C2 (ru) 2005-04-04 2011-07-11 Аб Сьянс Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы
NZ563444A (en) * 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2009521490A (ja) * 2005-12-22 2009-06-04 スミスクライン ビーチャム コーポレーション 化合物
WO2007087419A2 (en) 2006-01-24 2007-08-02 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EA017865B1 (ru) * 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EP2146740A4 (en) 2007-04-13 2010-05-26 Agency Science Tech & Res METHOD FOR CONTROLLING TUMORIGENESIS AND DIAGNOSIS OF THE RISK
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101909630A (zh) 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
RU2012109233A (ru) 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
AU2010319964A1 (en) 2009-11-16 2012-06-07 The Regents Of The University Of California Kinase inhibitors
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2890706A1 (en) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
JP2015537033A (ja) 2012-11-15 2015-12-24 ファーマサイクリックス，インク． キナーゼ阻害剤としてのピロロピリミジン化合物
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
AR097204A1 (es) 2013-08-02 2016-02-24 Pharmacyclics Inc Métodos de tratamiento de tumores sólidos
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
US9624224B2 (en) 2013-09-30 2017-04-18 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
KR20250151619A (ko) * 2017-06-30 2025-10-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI922347L (fi) * 1990-01-05 1992-05-22 Pfizer Azaoxindolderivat.
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.

Also Published As

Publication number Publication date
ATE181074T1 (de) 1999-06-15
PL304894A1 (en) 1995-01-09
JP3507497B2 (ja) 2004-03-15
ZA939578B (en) 1994-08-11
HUT67431A (en) 1995-04-28
TW296383B (enExample) 1997-01-21
FI943838A7 (fi) 1994-08-19
WO1994014808A1 (en) 1994-07-07
JPH07504208A (ja) 1995-05-11
IL108087A (en) 1997-09-30
CA2126228A1 (en) 1994-07-07
MY109695A (en) 1997-04-30
GR3030941T3 (en) 1999-11-30
CN1093707A (zh) 1994-10-19
KR950700296A (ko) 1995-01-16
ES2134926T3 (es) 1999-10-16
AU670488B2 (en) 1996-07-18
DE69325262D1 (de) 1999-07-15
NZ259330A (en) 1995-12-21
US5397787A (en) 1995-03-14
GB9226855D0 (en) 1993-02-17
MX9400206A (es) 1994-07-29
RU94040390A (ru) 1997-05-27
HU9401950D0 (en) 1994-09-28
DK0626963T3 (da) 1999-12-13
EP0626963A1 (en) 1994-12-07
DE69325262T2 (de) 2000-01-20
IL108087A0 (en) 1994-04-12
AU5810594A (en) 1994-07-19
EP0626963B1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
FI943838A0 (fi) Vinyleeniatsaindolijohdannaiset ja menetelmä niiden valmistamiseksi
FI921030A0 (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
PT97888A (pt) Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
ES2131207T3 (es) Derivados de amidas del acido valproico y 2-valproenoico y su uso como anticonvulsivos.
EP0564739A3 (enExample)
FI842419A0 (fi) 2-pyrimidinyl-1-piperazin-derivat, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
FI101376B1 (fi) Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi
FI933903A0 (fi) Substituerade cyklohexanderivat, foerfarande foer framstaellning daerav och anvaendning av foereningar foer behandling av sjukdomar
FI873064A0 (fi) Stabiliserade oxazafosforinloesningar och foerfarande foer framstaellning av dessa.
FI930171A0 (fi) Piperidinfoereningar, framstaellning och anvaendning av dessa
NZ248794A (en) 3-carboxy-(and phosphonoxy-)alkatriene-substituted chromene derivatives and medicaments
GR3023757T3 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents.
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
ATE30152T1 (de) 1-methyl-5-nitro-imidazolin-derivate und diese enthaltende therapeutische zusammensetzungen.
SE9203824L (sv) Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
SE8103983L (sv) Heterocykliska foreningar, deras framstellning och farmaceutiska kompositioner innehallande dessa
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
ITMI920082A1 (it) Derivati solforati di acidi biliari
PT90815A (pt) Processo de preparacao de derivados da fenotiazina
ATE4313T1 (de) Tyrosin-derivate, verfahren zu deren herstellung und eine sie enthaltende pharmazeutische zusammensetzung zur behandlung von hypertonie.
FI911616A0 (fi) Substituerade 3-tia- eller 3-oxa-alkyl -flavoner, foerfarande foer deras framstaellning, deras anvaendning, pao dessa foereningar baserade laekemedel samt mellanprodukter.
IT1255728B (it) Derivati di s-triazina ad azione fotoprotettiva
IT1237506B (it) Derivati amminici di 2,3-diaza-antracene-9,10-dioni come farmaci antitumorali

Legal Events

Date Code Title Description
FD Application lapsed